person · Reporting owner

MACKEY CATHERINE J

Disclosed activity across 7 companies

Tapewire entity: 36683
SEC CIK: 0001645330

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
IDEAYA Biosciences, Inc.IDYA · Entity 4069	Director	June 16, 2026	June 18, 2026
Poseida Therapeutics, Inc.PSTX · Entity 84243	Director	July 09, 2020	July 13, 2020
Voyager Therapeutics, Inc.VYGR · Entity 6271	Director	June 09, 2026	June 11, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

IDEAYA Biosciences, Inc.

Report date June 16, 2026 · Filed June 18, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.57 · Expires 2036-06-16	Direct	20,000	Reported balance After 2026-06-16 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-16 · Grant · Acquired 20,000 · Balance 20,000 F1: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date.

Poseida Therapeutics, Inc.

Report date July 09, 2020 · Filed July 13, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2030-07-08	Direct	20,000	Reported balance After 2020-07-09 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2020-07-09 · Grant · Acquired 20,000 · Balance 20,000 F1: The stock option will vest and become exercisable in 12 equal monthly installments from the date of grant.

Filing footnotes · ownership attribution and instrument terms

F1: The stock option will vest and become exercisable in 12 equal monthly installments from the date of grant.

Voyager Therapeutics, Inc.

Report date June 09, 2026 · Filed June 11, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.43 · Expires 2036-06-09	Direct	30,000	Reported balance After 2026-06-09 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-09 · Grant · Acquired 30,000 · Balance 30,000 F1: This stock option was issued pursuant to the 2025 Stock Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service as a director.

Filing footnotes · ownership attribution and instrument terms

F1: This stock option was issued pursuant to the 2025 Stock Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service as a director.

Past disclosures · reporting ended (4)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Avid Bioservices, Inc.

Report date February 05, 2025 · Filed February 07, 2025

Section 16 reporting ended · disclosed 2025-02-07. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, $0.001 par valueSEC Table I · non-derivative	Direct	0	Reported balance After 2025-02-05 transaction · row 1 1 source row Row 1 · 2025-02-05 · Disposition to issuer · Disposed 43,379 · Balance 0 F1: Represents shares of common stock that were disposed of at the effective time (the "Effective Time") of the merger (the "Merger") of Space Mergerco, Inc. ("Merger Sub") with and into Avid Bioservices, Inc. (the "Issuer") pursuant to the Agreement and Plan of Merger, dated as of November 6, 2024 (the "Merger Agreement"), by and among the Issuer, Space Finco, Inc., and Merger Sub. F2: At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive a cash payment per share of $12.50, without interest, subject to the terms and conditions of the Merger Agreement (the "Merger Consideration").
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.38 · Expires 2026-07-25	Direct	29,705	Reported balance After 2025-02-05 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2025-02-05 · Disposition to issuer · Disposed 32,100 · Balance 29,705 F3: Represents stock options ("Options") that were disposed of at the Effective Time of the Merger of Merger Sub with and into the Issuer pursuant to the Merger Agreement, by and among the Issuer, Space Finco, Inc., and Merger Sub. F4: This Option was fully vested at the Effective Time. At the Effective Time, each fully vested Option was cancelled and converted solely into the right to receive a cash payment equal to the product of (a) the total number of shares of common stock subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess, if any, of the Merger Consideration over the per share exercise price of such vested Option, without interest, subject to the terms and conditions of the Merger Agreement.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.87 · Expires 2027-01-09	Direct	10,030	Reported balance After 2025-02-05 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2025-02-05 · Disposition to issuer · Disposed 19,675 · Balance 10,030 F3: Represents stock options ("Options") that were disposed of at the Effective Time of the Merger of Merger Sub with and into the Issuer pursuant to the Merger Agreement, by and among the Issuer, Space Finco, Inc., and Merger Sub. F4: This Option was fully vested at the Effective Time. At the Effective Time, each fully vested Option was cancelled and converted solely into the right to receive a cash payment equal to the product of (a) the total number of shares of common stock subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess, if any, of the Merger Consideration over the per share exercise price of such vested Option, without interest, subject to the terms and conditions of the Merger Agreement.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.72 · Expires 2027-12-14	Direct	0	Reported balance After 2025-02-05 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2025-02-05 · Disposition to issuer · Disposed 10,030 · Balance 0 F3: Represents stock options ("Options") that were disposed of at the Effective Time of the Merger of Merger Sub with and into the Issuer pursuant to the Merger Agreement, by and among the Issuer, Space Finco, Inc., and Merger Sub. F4: This Option was fully vested at the Effective Time. At the Effective Time, each fully vested Option was cancelled and converted solely into the right to receive a cash payment equal to the product of (a) the total number of shares of common stock subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess, if any, of the Merger Consideration over the per share exercise price of such vested Option, without interest, subject to the terms and conditions of the Merger Agreement.
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	0	Reported balance After 2025-02-05 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2025-02-05 · Disposition to issuer · Disposed 8,147 · Balance 0 F5: Represents restricted stock units ("RSUs") that were disposed of at the Effective Time of the Merger of Merger Sub with and into the Issuer pursuant to the Merger Agreement, by and among the Issuer, Space Finco, Inc., and Merger Sub. F6: At the Effective Time, each unvested RSU was cancelled and converted solely into the right to receive a cash payment of $12.50 per share of common stock subject to such unvested RSU, without interest, subject to the terms and conditions of the Merger Agreement.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares of common stock that were disposed of at the effective time (the "Effective Time") of the merger (the "Merger") of Space Mergerco, Inc. ("Merger Sub") with and into Avid Bioservices, Inc. (the "Issuer") pursuant to the Agreement and Plan of Merger, dated as of November 6, 2024 (the "Merger Agreement"), by and among the Issuer, Space Finco, Inc., and Merger Sub.

F2: At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive a cash payment per share of $12.50, without interest, subject to the terms and conditions of the Merger Agreement (the "Merger Consideration").

F3: Represents stock options ("Options") that were disposed of at the Effective Time of the Merger of Merger Sub with and into the Issuer pursuant to the Merger Agreement, by and among the Issuer, Space Finco, Inc., and Merger Sub.

F4: This Option was fully vested at the Effective Time. At the Effective Time, each fully vested Option was cancelled and converted solely into the right to receive a cash payment equal to the product of (a) the total number of shares of common stock subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess, if any, of the Merger Consideration over the per share exercise price of such vested Option, without interest, subject to the terms and conditions of the Merger Agreement.

F5: Represents restricted stock units ("RSUs") that were disposed of at the Effective Time of the Merger of Merger Sub with and into the Issuer pursuant to the Merger Agreement, by and among the Issuer, Space Finco, Inc., and Merger Sub.

F6: At the Effective Time, each unvested RSU was cancelled and converted solely into the right to receive a cash payment of $12.50 per share of common stock subject to such unvested RSU, without interest, subject to the terms and conditions of the Merger Agreement.

GW PHARMACEUTICALS PLC

Report date May 05, 2021 · Filed May 07, 2021

Section 16 reporting ended · disclosed 2021-05-07. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	Reported balance After 2021-05-05 transaction · row 1 1 source row Row 1 · 2021-05-05 · Disposition to issuer · Disposed 10,536 · Balance 0 F1: On May 5, 2021, Jazz Pharmaceuticals Public Limited Company, a public limited company incorporated in the Republic of Ireland ("Jazz"), Jazz Pharmaceuticals UK Holdings Limited, a private limited company incorporated in England and Wales and an indirect wholly owned subsidiary of Jazz ("Bidco") and the DR Nominee (as defined in the Transaction Agreement) acquired all outstanding ordinary shares, par value British Pound Sterling 0.001 per share, of GW Pharmaceuticals plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement") (continued in footnote 2). F2: At the effective time of the Scheme of Arrangement, Scheme Shareholders (as defined in the Scheme of Arrangement) became entitled to receive for each Scheme Share (as defined in the Scheme of Arrangement) held by them an amount equal to $16.66 2/3 in cash plus 0.010030 ordinary shares, nominal value $0.0001 per share, of Jazz ("Jazz ordinary shares"). The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 15, 2021.
Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $11.17 · Expires 2028-01-03	Direct	Reported balance After 2021-05-05 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-05-05 · Disposition to issuer · Disposed 35,340 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration.
Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $14.33 · Expires 2029-03-01	Direct	Reported balance After 2021-05-05 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2021-05-05 · Disposition to issuer · Disposed 16,548 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration.
Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2021-05-05 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2021-05-05 · Disposition to issuer · Disposed 3,144 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F4: These stock options were granted with automatic vesting on exercisable date.
Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2021-05-05 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2021-05-05 · Disposition to issuer · Disposed 34,416 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F4: These stock options were granted with automatic vesting on exercisable date.
Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2021-05-05 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2021-05-05 · Disposition to issuer · Disposed 22,464 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F4: These stock options were granted with automatic vesting on exercisable date.

Filing footnotes · ownership attribution and instrument terms

F1: On May 5, 2021, Jazz Pharmaceuticals Public Limited Company, a public limited company incorporated in the Republic of Ireland ("Jazz"), Jazz Pharmaceuticals UK Holdings Limited, a private limited company incorporated in England and Wales and an indirect wholly owned subsidiary of Jazz ("Bidco") and the DR Nominee (as defined in the Transaction Agreement) acquired all outstanding ordinary shares, par value British Pound Sterling 0.001 per share, of GW Pharmaceuticals plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement") (continued in footnote 2).

F2: At the effective time of the Scheme of Arrangement, Scheme Shareholders (as defined in the Scheme of Arrangement) became entitled to receive for each Scheme Share (as defined in the Scheme of Arrangement) held by them an amount equal to $16.66 2/3 in cash plus 0.010030 ordinary shares, nominal value $0.0001 per share, of Jazz ("Jazz ordinary shares"). The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 15, 2021.

F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration.

F4: These stock options were granted with automatic vesting on exercisable date.

SEQUENOM INC

Report date September 07, 2016 · Filed September 07, 2016

Section 16 reporting ended · disclosed 2016-09-07. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2016-09-07 transaction · row 1 1 source row Row 1 · 2016-09-07 · Other · Disposed 21,114 · Balance 0 F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated July 26, 2016, among the Issuer, Laboratory Corporation of America Holdings, a Delaware corporation ("Parent"), and Savoy Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser") in exchange for a cash consideration of $2.40 per share, without interest, subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger").
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.11 · Expires 2026-06-14	Direct	Reported balance After 2016-09-07 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2016-09-07 · Disposition to issuer · Disposed 20,000 · Balance 0 F2: This option was cancelled in the Merger in exchange for a cash payment equal to $2.40 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.60 · Expires 2026-01-03	Direct	Reported balance After 2016-09-07 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2016-09-07 · Disposition to issuer · Disposed 8,571 · Balance 0 F2: This option was cancelled in the Merger in exchange for a cash payment equal to $2.40 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated July 26, 2016, among the Issuer, Laboratory Corporation of America Holdings, a Delaware corporation ("Parent"), and Savoy Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser") in exchange for a cash consideration of $2.40 per share, without interest, subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger").

F2: This option was cancelled in the Merger in exchange for a cash payment equal to $2.40 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.

Trillium Therapeutics Inc.

Report date November 17, 2021 · Filed November 19, 2021

Section 16 reporting ended · disclosed 2021-11-19. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.70 · Expires 2031-07-01	Direct	0	Reported balance After 2021-11-17 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2021-11-17 · Disposition to issuer · Disposed 67,000 · Balance 0 F1: On November 17, 2021 (the "Closing Date"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the "Purchaser") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the "Issuer") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the "Plan of Arrangement"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the "Effective Time") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash.

Filing footnotes · ownership attribution and instrument terms

F1: On November 17, 2021 (the "Closing Date"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the "Purchaser") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the "Issuer") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the "Plan of Arrangement"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the "Effective Time") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 16, 2026 Filed Jun 18, 2026 20:32 UTC	IDEAYA Biosciences, Inc. IDYA · Entity 4069	GrantStock Option (right to buy) · Derivative	20,000	$0.00 Strike: $30.57	$0.00	Disclosure SEC source: 0001610717-26-000260 · form4.xml · derivative · entry 1 MACKEY CATHERINE J · CIK 0001645330 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2036-06-16 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date. Read SEC document
June 09, 2026 Filed Jun 11, 2026 20:05 UTC	Voyager Therapeutics, Inc. VYGR · Entity 6271	GrantStock Option (Right to Buy) · Derivative	30,000	$0.00 Strike: $3.43	$0.00	Disclosure SEC source: 0001104659-26-072927 · tm2617547-8_4seq1.xml · derivative · entry 1 MACKEY CATHERINE J · CIK 0001645330 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2036-06-09 F1 · derivative.exercise_date: This stock option was issued pursuant to the 2025 Stock Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service as a director. Read SEC document
June 24, 2025 Filed Jun 26, 2025 20:54 UTC	IDEAYA Biosciences, Inc. IDYA · Entity 4069	GrantStock Option (right to buy) · Derivative	20,000	$0.00 Strike: $21.78	$0.00	Disclosure SEC source: 0001610717-25-000261 · form4.xml · derivative · entry 1 MACKEY CATHERINE J · CIK 0001645330 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2035-06-24 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date. Read SEC document
June 03, 2025 Filed Jun 5, 2025 01:03 UTC	Voyager Therapeutics, Inc. VYGR · Entity 6271	GrantStock Option (Right to Buy) · Derivative	24,000	$0.00 Strike: $3.28	$0.00	Disclosure SEC source: 0001104659-25-056564 · tm2517191-5_4seq1.xml · derivative · entry 1 MACKEY CATHERINE J · CIK 0001645330 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2035-06-03 F1 · derivative.exercise_date: This stock option was issued pursuant to the 2025 Stock Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service as a director. Read SEC document
February 05, 2025 Filed Feb 7, 2025 19:39 UTC	Avid Bioservices, Inc. CDMO · Entity 83494	Disposition to issuerRestricted Stock Units · Derivative	8,147	Not disclosed Strike: $0.00	Not disclosed	Disclosure SEC source: 0001683168-25-000860 · ownership.xml · derivative · entry 5 MACKEY CATHERINE J · CIK 0001645330 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,147 shares Expires not disclosed F5 · shares: Represents restricted stock units ("RSUs") that were disposed of at the Effective Time of the Merger of Merger Sub with and into the Issuer pursuant to the Merger Agreement, by and among the Issuer, Space Finco, Inc., and Merger Sub. F6 · price: At the Effective Time, each unvested RSU was cancelled and converted solely into the right to receive a cash payment of $12.50 per share of common stock subject to such unvested RSU, without interest, subject to the terms and conditions of the Merger Agreement. F6 · derivative.exercise_date: At the Effective Time, each unvested RSU was cancelled and converted solely into the right to receive a cash payment of $12.50 per share of common stock subject to such unvested RSU, without interest, subject to the terms and conditions of the Merger Agreement. F6 · derivative.expiration_date: At the Effective Time, each unvested RSU was cancelled and converted solely into the right to receive a cash payment of $12.50 per share of common stock subject to such unvested RSU, without interest, subject to the terms and conditions of the Merger Agreement. Read SEC document
February 05, 2025 Filed Feb 7, 2025 19:39 UTC	Avid Bioservices, Inc. CDMO · Entity 83494	Disposition to issuerStock Option (right to buy) · Derivative	10,030	Not disclosed Strike: $10.72	Not disclosed	Disclosure SEC source: 0001683168-25-000860 · ownership.xml · derivative · entry 4 MACKEY CATHERINE J · CIK 0001645330 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,030 shares Expires 2027-12-14 F3 · shares: Represents stock options ("Options") that were disposed of at the Effective Time of the Merger of Merger Sub with and into the Issuer pursuant to the Merger Agreement, by and among the Issuer, Space Finco, Inc., and Merger Sub. F4 · price: This Option was fully vested at the Effective Time. At the Effective Time, each fully vested Option was cancelled and converted solely into the right to receive a cash payment equal to the product of (a) the total number of shares of common stock subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess, if any, of the Merger Consideration over the per share exercise price of such vested Option, without interest, subject to the terms and conditions of the Merger Agreement. F4 · derivative.exercise_date: This Option was fully vested at the Effective Time. At the Effective Time, each fully vested Option was cancelled and converted solely into the right to receive a cash payment equal to the product of (a) the total number of shares of common stock subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess, if any, of the Merger Consideration over the per share exercise price of such vested Option, without interest, subject to the terms and conditions of the Merger Agreement. Read SEC document
February 05, 2025 Filed Feb 7, 2025 19:39 UTC	Avid Bioservices, Inc. CDMO · Entity 83494	Disposition to issuerStock Option (right to buy) · Derivative	19,675	Not disclosed Strike: $6.87	Not disclosed	Disclosure SEC source: 0001683168-25-000860 · ownership.xml · derivative · entry 3 MACKEY CATHERINE J · CIK 0001645330 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,030 Underlying: Common Stock · 19,675 shares Expires 2027-01-09 F3 · shares: Represents stock options ("Options") that were disposed of at the Effective Time of the Merger of Merger Sub with and into the Issuer pursuant to the Merger Agreement, by and among the Issuer, Space Finco, Inc., and Merger Sub. F4 · price: This Option was fully vested at the Effective Time. At the Effective Time, each fully vested Option was cancelled and converted solely into the right to receive a cash payment equal to the product of (a) the total number of shares of common stock subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess, if any, of the Merger Consideration over the per share exercise price of such vested Option, without interest, subject to the terms and conditions of the Merger Agreement. F4 · derivative.exercise_date: This Option was fully vested at the Effective Time. At the Effective Time, each fully vested Option was cancelled and converted solely into the right to receive a cash payment equal to the product of (a) the total number of shares of common stock subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess, if any, of the Merger Consideration over the per share exercise price of such vested Option, without interest, subject to the terms and conditions of the Merger Agreement. Read SEC document
February 05, 2025 Filed Feb 7, 2025 19:39 UTC	Avid Bioservices, Inc. CDMO · Entity 83494	Disposition to issuerStock Option (right to buy) · Derivative	32,100	Not disclosed Strike: $6.38	Not disclosed	Disclosure SEC source: 0001683168-25-000860 · ownership.xml · derivative · entry 2 MACKEY CATHERINE J · CIK 0001645330 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,705 Underlying: Common Stock · 32,100 shares Expires 2026-07-25 F3 · shares: Represents stock options ("Options") that were disposed of at the Effective Time of the Merger of Merger Sub with and into the Issuer pursuant to the Merger Agreement, by and among the Issuer, Space Finco, Inc., and Merger Sub. F4 · price: This Option was fully vested at the Effective Time. At the Effective Time, each fully vested Option was cancelled and converted solely into the right to receive a cash payment equal to the product of (a) the total number of shares of common stock subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess, if any, of the Merger Consideration over the per share exercise price of such vested Option, without interest, subject to the terms and conditions of the Merger Agreement. F4 · derivative.exercise_date: This Option was fully vested at the Effective Time. At the Effective Time, each fully vested Option was cancelled and converted solely into the right to receive a cash payment equal to the product of (a) the total number of shares of common stock subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess, if any, of the Merger Consideration over the per share exercise price of such vested Option, without interest, subject to the terms and conditions of the Merger Agreement. Read SEC document
February 05, 2025 Filed Feb 7, 2025 19:39 UTC	Avid Bioservices, Inc. CDMO · Entity 83494	Disposition to issuerCommon Stock, $0.001 par value	43,379	Not disclosed	Not disclosed	Disclosure SEC source: 0001683168-25-000860 · ownership.xml · nonDerivative · entry 1 MACKEY CATHERINE J · CIK 0001645330 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: Represents shares of common stock that were disposed of at the effective time (the "Effective Time") of the merger (the "Merger") of Space Mergerco, Inc. ("Merger Sub") with and into Avid Bioservices, Inc. (the "Issuer") pursuant to the Agreement and Plan of Merger, dated as of November 6, 2024 (the "Merger Agreement"), by and among the Issuer, Space Finco, Inc., and Merger Sub. F2 · price: At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive a cash payment per share of $12.50, without interest, subject to the terms and conditions of the Merger Agreement (the "Merger Consideration"). Read SEC document
December 14, 2024 Filed Dec 17, 2024 19:48 UTC	Avid Bioservices, Inc. CDMO · Entity 83494	GrantRestricted Stock Units · Derivative	8,147	$0.00	$0.00	Disclosure SEC source: 0001683168-24-008803 · ownership.xml · derivative · entry 3 MACKEY CATHERINE J · CIK 0001645330 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,147 Underlying: Common Stock · 8,147 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting, one share of the Issuer's Common Stock. F3 · kind: Annual equity award grant pursuant to the Issuer's non-employee director compensation program. F4 · derivative.exercise_date: RSUs granted to the reporting person on December 14, 2024 shall fully vest on December 14, 2025, subject to the reporting person's continuous service to the Issuer on such vesting date. F4 · derivative.expiration_date: RSUs granted to the reporting person on December 14, 2024 shall fully vest on December 14, 2025, subject to the reporting person's continuous service to the Issuer on such vesting date. Read SEC document
December 14, 2024 Filed Dec 17, 2024 19:48 UTC	Avid Bioservices, Inc. CDMO · Entity 83494	Exercise / conversionRestricted Stock Units · Derivative	26,756	$0.00	$0.00	Disclosure SEC source: 0001683168-24-008803 · ownership.xml · derivative · entry 2 MACKEY CATHERINE J · CIK 0001645330 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,756 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting, one share of the Issuer's Common Stock. F2 · derivative.exercise_date: RSUs granted to the reporting person on December 14, 2023 pursuant to the Issuer's non-employee director compensation program fully vested on December 14, 2024. F2 · derivative.expiration_date: RSUs granted to the reporting person on December 14, 2023 pursuant to the Issuer's non-employee director compensation program fully vested on December 14, 2024. Read SEC document
December 14, 2024 Filed Dec 17, 2024 19:48 UTC	Avid Bioservices, Inc. CDMO · Entity 83494	Exercise / conversionCommon Stock, $0.001 par value	26,756	Not disclosed	Not disclosed	Disclosure SEC source: 0001683168-24-008803 · ownership.xml · nonDerivative · entry 1 MACKEY CATHERINE J · CIK 0001645330 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,379 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting, one share of the Issuer's Common Stock. Read SEC document
June 05, 2024 Filed Jun 7, 2024 20:19 UTC	Voyager Therapeutics, Inc. VYGR · Entity 6271	GrantStock Option (Right to Buy) · Derivative	24,000	$0.00 Strike: $8.70	$0.00	Disclosure SEC source: 0001104659-24-069662 · tm2416702-5_4seq1.xml · derivative · entry 1 MACKEY CATHERINE J · CIK 0001645330 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2034-06-05 F1 · derivative.exercise_date: This stock option was issued pursuant to the 2015 Stock Option and Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service as a director. Read SEC document
May 31, 2024 Filed May 31, 2024 20:30 UTC	IDEAYA Biosciences, Inc. IDYA · Entity 4069	GrantStock Option (right to buy) · Derivative	16,200	$0.00 Strike: $36.55	$0.00	Disclosure SEC source: 0001610717-24-000273 · form4.xml · derivative · entry 1 MACKEY CATHERINE J · CIK 0001645330 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,200 Underlying: Common Stock · 16,200 shares Expires 2034-05-30 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date. Read SEC document
December 14, 2023 Filed Dec 18, 2023 19:32 UTC	Avid Bioservices, Inc. CDMO · Entity 83494	GrantRestricted Stock Units · Derivative	26,756	$0.00	$0.00	Disclosure SEC source: 0001683168-23-008942 · ownership.xml · derivative · entry 3 MACKEY CATHERINE J · CIK 0001645330 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,756 Underlying: Common Stock · 26,756 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting, one share of the Issuer's Common Stock. F3 · kind: Annual equity award grant pursuant to the Issuer's non-employee director compensation program. F4 · derivative.exercise_date: RSUs granted to the reporting person on December 14, 2023 shall fully vest on December 14, 2024, subject to the reporting person's continuous service to the Issuer on such vesting date. F4 · derivative.expiration_date: RSUs granted to the reporting person on December 14, 2023 shall fully vest on December 14, 2024, subject to the reporting person's continuous service to the Issuer on such vesting date. Read SEC document
December 14, 2023 Filed Dec 18, 2023 19:32 UTC	Avid Bioservices, Inc. CDMO · Entity 83494	Exercise / conversionRestricted Stock Units · Derivative	9,612	$0.00	$0.00	Disclosure SEC source: 0001683168-23-008942 · ownership.xml · derivative · entry 2 MACKEY CATHERINE J · CIK 0001645330 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,612 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting, one share of the Issuer's Common Stock. F2 · derivative.exercise_date: RSUs granted to the reporting person on December 14, 2022 pursuant to the Issuer's non-employee director compensation program fully vested on December 14, 2023. F2 · derivative.expiration_date: RSUs granted to the reporting person on December 14, 2022 pursuant to the Issuer's non-employee director compensation program fully vested on December 14, 2023. Read SEC document
December 14, 2023 Filed Dec 18, 2023 19:32 UTC	Avid Bioservices, Inc. CDMO · Entity 83494	Exercise / conversionCommon Stock, $0.001 par value	9,612	Not disclosed	Not disclosed	Disclosure SEC source: 0001683168-23-008942 · ownership.xml · nonDerivative · entry 1 MACKEY CATHERINE J · CIK 0001645330 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,623 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting, one share of the Issuer's Common Stock. Read SEC document
June 07, 2023 Filed Jun 9, 2023 20:46 UTC	IDEAYA Biosciences, Inc. IDYA · Entity 4069	GrantStock Option (right to buy) · Derivative	16,200	$0.00 Strike: $25.40	$0.00	Disclosure SEC source: 0001610717-23-000113 · form4.xml · derivative · entry 1 MACKEY CATHERINE J · CIK 0001645330 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,200 Underlying: Common Stock · 16,200 shares Expires 2033-06-06 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date. Read SEC document
June 06, 2023 Filed Jun 7, 2023 20:40 UTC	Voyager Therapeutics, Inc. VYGR · Entity 6271	GrantStock Option (Right to Buy) · Derivative	22,000	$0.00 Strike: $12.57	$0.00	Disclosure SEC source: 0001104659-23-068932 · tm2317994-8_4seq1.xml · derivative · entry 1 MACKEY CATHERINE J · CIK 0001645330 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2033-06-06 F1 · derivative.exercise_date: This stock option was issued pursuant to the 2015 Stock Option and Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service as a director. Read SEC document
December 14, 2022 Filed Dec 16, 2022 20:01 UTC	Avid Bioservices, Inc. CDMO · Entity 83494	GrantRestricted Stock Units · Derivative	9,612	$0.00	$0.00	Disclosure SEC source: 0001683168-22-008497 · ownership.xml · derivative · entry 3 MACKEY CATHERINE J · CIK 0001645330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,612 Underlying: Common Stock · 9,612 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting, one share of the Issuer's Common Stock. F3 · kind: Annual equity award grant pursuant to the Issuer's non-employee director compensation program. F4 · derivative.exercise_date: The RSUs granted to the reported person on December 14, 2022 shall fully vest on December 14, 2023, subject to the reporting person's continuous service to the Issuer on such vesting date. F4 · derivative.expiration_date: The RSUs granted to the reported person on December 14, 2022 shall fully vest on December 14, 2023, subject to the reporting person's continuous service to the Issuer on such vesting date. Read SEC document
December 14, 2022 Filed Dec 16, 2022 20:01 UTC	Avid Bioservices, Inc. CDMO · Entity 83494	Exercise / conversionRestricted Stock Units · Derivative	4,632	$0.00	$0.00	Disclosure SEC source: 0001683168-22-008497 · ownership.xml · derivative · entry 2 MACKEY CATHERINE J · CIK 0001645330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,632 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting, one share of the Issuer's Common Stock. F2 · derivative.exercise_date: RSUs granted to the reporting person on December 14, 2021 pursuant to the Issuer's non-employee director compensation program which fully vested on December 14, 2022. F2 · derivative.expiration_date: RSUs granted to the reporting person on December 14, 2021 pursuant to the Issuer's non-employee director compensation program which fully vested on December 14, 2022. Read SEC document
December 14, 2022 Filed Dec 16, 2022 20:01 UTC	Avid Bioservices, Inc. CDMO · Entity 83494	Exercise / conversionCommon Stock, $0.001 par value	4,632	Not disclosed	Not disclosed	Disclosure SEC source: 0001683168-22-008497 · ownership.xml · nonDerivative · entry 1 MACKEY CATHERINE J · CIK 0001645330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,011 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting, one share of the Issuer's Common Stock. Read SEC document
August 15, 2022 Filed Aug 16, 2022 21:03 UTC	Voyager Therapeutics, Inc. VYGR · Entity 6271	GrantStock Option (Right to Buy) · Derivative	44,000	$0.00 Strike: $6.02	$0.00	Disclosure SEC source: 0001104659-22-091816 · tm2223558-2_4seq1.xml · derivative · entry 1 MACKEY CATHERINE J · CIK 0001645330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,000 Underlying: Common Stock · 44,000 shares Expires 2032-08-15 F1 · derivative.exercise_date: This stock option was issued pursuant to the 2015 Stock Option and Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. The option vests over four years, with 1/16th of the shares of common stock underlying the option vesting upon the three-month anniversary of the Vesting Commencement Date and an additional 1/16th of the shares of common stock underlying the option vesting at the end of each successive three-month period thereafter, subject to the Reporting Person's continued service as a director. Read SEC document
April 05, 2022 Filed Apr 6, 2022 20:23 UTC	IDEAYA Biosciences, Inc. IDYA · Entity 4069	GrantStock Option (Right to Buy) · Derivative	22,000	$0.00 Strike: $11.80	$0.00	Disclosure SEC source: 0001567619-22-008194 · doc1.xml · derivative · entry 1 MACKEY CATHERINE J · CIK 0001645330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2032-04-04 F1 · derivative.exercise_date: 1/36th of the shares subject to the option vest on each monthly anniversary measured from April 5, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date. Read SEC document
December 14, 2021 Filed Dec 16, 2021 21:33 UTC	Avid Bioservices, Inc. CDMO · Entity 83494	GrantRestricted Stock Units · Derivative	4,632	$0.00	$0.00	Disclosure SEC source: 0001683168-21-006438 · ownership.xml · derivative · entry 3 MACKEY CATHERINE J · CIK 0001645330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,632 Underlying: Common Stock · 4,632 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting, one share of the Issuer's Common Stock. F3 · kind: Annual equity award grant pursuant to the Issuer's non-employee director compensation program. F4 · derivative.exercise_date: The RSUs granted to the reporting person shall fully vest on December 14, 2022, subject to the reporting person's continuous service to the Issuer on such vesting date. F4 · derivative.expiration_date: The RSUs granted to the reporting person shall fully vest on December 14, 2022, subject to the reporting person's continuous service to the Issuer on such vesting date. Read SEC document
December 14, 2021 Filed Dec 16, 2021 21:33 UTC	Avid Bioservices, Inc. CDMO · Entity 83494	Exercise / conversionRestricted Stock Units · Derivative	2,379	$0.00	$0.00	Disclosure SEC source: 0001683168-21-006438 · ownership.xml · derivative · entry 2 MACKEY CATHERINE J · CIK 0001645330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,379 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting, one share of the Issuer's Common Stock. F2 · derivative.exercise_date: RSUs granted to the reporting person on December 14, 2020 fully vested on December 14, 2021. F2 · derivative.expiration_date: RSUs granted to the reporting person on December 14, 2020 fully vested on December 14, 2021. Read SEC document
December 14, 2021 Filed Dec 16, 2021 21:33 UTC	Avid Bioservices, Inc. CDMO · Entity 83494	Exercise / conversionCommon Stock, $0.001 par value	2,379	Not disclosed	Not disclosed	Disclosure SEC source: 0001683168-21-006438 · ownership.xml · nonDerivative · entry 1 MACKEY CATHERINE J · CIK 0001645330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,379 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting, one share of the Issuer's Common Stock. Read SEC document
November 17, 2021 Filed Nov 19, 2021 13:26 UTC	Trillium Therapeutics Inc. TRIL · Entity 133265	Disposition to issuerStock Option (Right to Buy) · Derivative	67,000	$0.00 Strike: $9.70	$0.00	Disclosure SEC source: 0001104659-21-141742 · tm2133436-8_4seq1.xml · derivative · entry 1 MACKEY CATHERINE J · CIK 0001645330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 67,000 shares Expires 2031-07-01 F1 · derivative.exercise_date: On November 17, 2021 (the "Closing Date"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the "Purchaser") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the "Issuer") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the "Plan of Arrangement"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the "Effective Time") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash. Read SEC document
July 01, 2021 Filed Jul 2, 2021 16:35 UTC	Trillium Therapeutics Inc. TRIL · Entity 133265	GrantStock Option (Right to Buy) · Derivative	67,000	$0.00 Strike: $9.70	$0.00	Disclosure SEC source: 0001062993-21-006276 · form4.xml · derivative · entry 1 MACKEY CATHERINE J · CIK 0001645330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,000 Underlying: Common Shares · 67,000 shares Expires 2031-07-01 F1 · derivative.exercise_date: One-third of the options vest on the one year anniversary of the grant date and the remaining options vest in equal quarterly installments over the following two years. Read SEC document
May 05, 2021 Filed May 7, 2021 16:15 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Disposition to issuerShare Options · Derivative	22,464	Not disclosed Strike: $0.00	Not disclosed	Disclosure SEC source: 0000899243-21-018662 · doc4.xml · derivative · entry 6 MACKEY CATHERINE J · CIK 0001645330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 22,464 shares Expires not disclosed F3 · price: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3 · derivative.exercise_date: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F4 · derivative.expiration_date: These stock options were granted with automatic vesting on exercisable date. Read SEC document
May 05, 2021 Filed May 7, 2021 16:15 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Disposition to issuerShare Options · Derivative	34,416	Not disclosed Strike: $0.00	Not disclosed	Disclosure SEC source: 0000899243-21-018662 · doc4.xml · derivative · entry 5 MACKEY CATHERINE J · CIK 0001645330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 34,416 shares Expires not disclosed F3 · price: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3 · derivative.exercise_date: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F4 · derivative.expiration_date: These stock options were granted with automatic vesting on exercisable date. Read SEC document
May 05, 2021 Filed May 7, 2021 16:15 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Disposition to issuerShare Options · Derivative	3,144	Not disclosed Strike: $0.00	Not disclosed	Disclosure SEC source: 0000899243-21-018662 · doc4.xml · derivative · entry 4 MACKEY CATHERINE J · CIK 0001645330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 3,144 shares Expires not disclosed F3 · price: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3 · derivative.exercise_date: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F4 · derivative.expiration_date: These stock options were granted with automatic vesting on exercisable date. Read SEC document
May 05, 2021 Filed May 7, 2021 16:15 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Disposition to issuerShare Options · Derivative	16,548	Not disclosed Strike: $14.33	Not disclosed	Disclosure SEC source: 0000899243-21-018662 · doc4.xml · derivative · entry 3 MACKEY CATHERINE J · CIK 0001645330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 16,548 shares Expires 2029-03-01 F3 · price: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3 · derivative.exercise_date: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. Read SEC document
May 05, 2021 Filed May 7, 2021 16:15 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Disposition to issuerShare Options · Derivative	35,340	Not disclosed Strike: $11.17	Not disclosed	Disclosure SEC source: 0000899243-21-018662 · doc4.xml · derivative · entry 2 MACKEY CATHERINE J · CIK 0001645330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 35,340 shares Expires 2028-01-03 F3 · price: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3 · derivative.exercise_date: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. Read SEC document
May 05, 2021 Filed May 7, 2021 16:15 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Disposition to issuerOrdinary Shares	10,536	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-21-018662 · doc4.xml · nonDerivative · entry 1 MACKEY CATHERINE J · CIK 0001645330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: On May 5, 2021, Jazz Pharmaceuticals Public Limited Company, a public limited company incorporated in the Republic of Ireland ("Jazz"), Jazz Pharmaceuticals UK Holdings Limited, a private limited company incorporated in England and Wales and an indirect wholly owned subsidiary of Jazz ("Bidco") and the DR Nominee (as defined in the Transaction Agreement) acquired all outstanding ordinary shares, par value British Pound Sterling 0.001 per share, of GW Pharmaceuticals plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement") (continued in footnote 2). F2 · price: At the effective time of the Scheme of Arrangement, Scheme Shareholders (as defined in the Scheme of Arrangement) became entitled to receive for each Scheme Share (as defined in the Scheme of Arrangement) held by them an amount equal to $16.66 2/3 in cash plus 0.010030 ordinary shares, nominal value $0.0001 per share, of Jazz ("Jazz ordinary shares"). The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 15, 2021. Read SEC document
March 01, 2021 Filed Mar 2, 2021 21:43 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Exercise / conversionShare Options · Derivative	3,144	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000899243-21-009228 · doc4.xml · derivative · entry 3 MACKEY CATHERINE J · CIK 0001645330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 3,144 shares Expires 2021-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.39 U.S. Dollars as of March 1, 2021. F1 · kind: Exercise of share options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. Read SEC document
March 01, 2021 Filed Mar 2, 2021 21:43 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Tax withholdingOrdinary Shares	1,260	$17.85	$22,491.00	Disclosure SEC source: 0000899243-21-009228 · doc4.xml · nonDerivative · entry 2 MACKEY CATHERINE J · CIK 0001645330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,536 F3 · kind: Mandatory withhold to cover vested RSU style share options. F4 · shares: Represented by ADS. F5 · price: The price reported is price per ordinary share converted from price per ADS. Read SEC document
March 01, 2021 Filed Mar 2, 2021 21:43 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Exercise / conversionOrdinary Shares	3,144	$0.00	$4.40	Disclosure SEC source: 0000899243-21-009228 · doc4.xml · nonDerivative · entry 1 MACKEY CATHERINE J · CIK 0001645330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,796 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise of share options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. F2 · price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.39 U.S. Dollars as of March 1, 2021. Read SEC document
February 22, 2021 Filed Feb 24, 2021 18:54 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	GrantShare Options · Derivative	22,464	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000899243-21-008102 · doc4.xml · derivative · entry 1 MACKEY CATHERINE J · CIK 0001645330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,464 Underlying: Ordinary Shares · 22,464 shares Expires not disclosed F1 · security: Granted pursuant to the Issuer's Long-Term Incentive Plan. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.41 U.S. Dollars as of February 22, 2021. F3 · derivative.exercise_date: These share options will vest in three equal annual installments beginning on February 22, 2022 and be automatically exercised upon vesting. F4 · derivative.exercise_date: Subject to accelerated vesting in connection with the closing of the transactions contemplated by the Transaction Agreement, dated as of February 3, 2021, by and among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals Public Limited Company and GW Pharmaceuticals plc. F3 · derivative.expiration_date: These share options will vest in three equal annual installments beginning on February 22, 2022 and be automatically exercised upon vesting. F4 · derivative.expiration_date: Subject to accelerated vesting in connection with the closing of the transactions contemplated by the Transaction Agreement, dated as of February 3, 2021, by and among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals Public Limited Company and GW Pharmaceuticals plc. Read SEC document
January 04, 2021 Filed Jan 6, 2021 21:31 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Exercise / conversionShare Options · Derivative	3,576	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000899243-21-000786 · doc4.xml · derivative · entry 3 MACKEY CATHERINE J · CIK 0001645330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4 Underlying: Ordinary Shares · 3,576 shares Expires 2021-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.37 U.S. Dollars as of January 4, 2020. F1 · kind: Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. Read SEC document
January 04, 2021 Filed Jan 6, 2021 21:31 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Tax withholdingOrdinary Shares	1,440	$9.62	$13,852.80	Disclosure SEC source: 0000899243-21-000786 · doc4.xml · nonDerivative · entry 2 MACKEY CATHERINE J · CIK 0001645330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,652 F4 · kind: Mandatory withhold to cover vested RSU style share options. F5 · shares: Represented by ADS. F6 · price: The price reported is price per ordinary share converted from price per ADS. Read SEC document
January 04, 2021 Filed Jan 6, 2021 21:31 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Exercise / conversionOrdinary Shares	3,576	$0.00	$5.01	Disclosure SEC source: 0000899243-21-000786 · doc4.xml · nonDerivative · entry 1 MACKEY CATHERINE J · CIK 0001645330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,092 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. F2 · price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.37 U.S. Dollars as of January 4, 2020. F3 · balance_after: Excluding 9,868 ordinary shares underlying RSU-style share options previously reported in Column 5 of Table I, of which 3,580 ordinary shares vested on January 4, 2021 and 6,288 ordinary shares have not vested. Excluding 8 ordinary shares erroneously included in Column 5 of Table I of previous form 4s. Read SEC document
December 14, 2020 Filed Dec 16, 2020 20:00 UTC	Avid Bioservices, Inc. CDMO · Entity 83494	GrantRestricted Stock Units · Derivative	2,379	$0.00	$0.00	Disclosure SEC source: 0001683168-20-004317 · ownership.xml · derivative · entry 2 MACKEY CATHERINE J · CIK 0001645330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,379 Underlying: Common Stock · 2,379 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's Common Stock. F1 · shares: Annual grant of equity awards pursuant to the Issuer's non-employee director compensation program. F2 · derivative.exercise_date: 100% of each equity award granted to the reporting person shall vest on December 14, 2021. F2 · derivative.expiration_date: 100% of each equity award granted to the reporting person shall vest on December 14, 2021. Read SEC document
December 14, 2020 Filed Dec 16, 2020 20:00 UTC	Avid Bioservices, Inc. CDMO · Entity 83494	GrantStock Option (right to buy) · Derivative	10,030	$0.00 Strike: $10.72	$0.00	Disclosure SEC source: 0001683168-20-004317 · ownership.xml · derivative · entry 1 MACKEY CATHERINE J · CIK 0001645330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,805 Underlying: Common Stock · 10,030 shares Expires 2027-12-14 F1 · shares: Annual grant of equity awards pursuant to the Issuer's non-employee director compensation program. F2 · derivative.exercise_date: 100% of each equity award granted to the reporting person shall vest on December 14, 2021. Read SEC document
July 09, 2020 Filed Jul 13, 2020 19:00 UTC	Poseida Therapeutics, Inc. PSTX · Entity 84243	GrantStock Option (Right to Buy) · Derivative	20,000	$0.00 Strike: $16.00	$0.00	Disclosure SEC source: 0001209191-20-042316 · doc4.xml · derivative · entry 1 MACKEY CATHERINE J · CIK 0001645330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-07-08 F1 · derivative.exercise_date: The stock option will vest and become exercisable in 12 equal monthly installments from the date of grant. Read SEC document
June 04, 2020 Filed Jun 8, 2020 20:04 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	GrantShare Options · Derivative	34,416	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000899243-20-015696 · doc4.xml · derivative · entry 1 MACKEY CATHERINE J · CIK 0001645330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,416 Underlying: Ordinary Shares · 34,416 shares Expires not disclosed F1 · security: Granted pursuant to the Issuer's Long-Term Incentive Plan. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.26 U.S. Dollars as of June 4, 2020. F3 · derivative.exercise_date: These share options will vest in three equal annual installments beginning on June 4, 2021 and be automatically exercised upon vesting. F3 · derivative.expiration_date: These share options will vest in three equal annual installments beginning on June 4, 2021 and be automatically exercised upon vesting. Read SEC document
March 02, 2020 Filed Mar 4, 2020 18:04 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	SaleOrdinary Shares	1,356	$8.35	$11,322.60	Disclosure SEC source: 0000899243-20-006999 · doc4.xml · nonDerivative · entry 1 MACKEY CATHERINE J · CIK 0001645330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,392 F1 · kind: Automatic sale to cover vested restricted stock units that have been previously reported in Column 5 of Table I. F2 · shares: Represented by American Depositary Shares of the Issuer ("ADS"). Each ADS represents twelve ordinary shares of the Issuer. F3 · price: The price reported is price per ordinary share converted from price per ADS. Read SEC document
January 09, 2020 Filed Jan 13, 2020 20:35 UTC	Avid Bioservices, Inc. CDMO · Entity 83494	GrantStock Option (right to buy) · Derivative	19,675	$0.00 Strike: $6.87	$0.00	Disclosure SEC source: 0001683168-20-000107 · ownership.xml · derivative · entry 1 MACKEY CATHERINE J · CIK 0001645330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,775 Underlying: Common Stock · 19,675 shares Expires 2027-01-09 F1 · shares: Annual grant of stock options pursuant to the Issuer's non-employee director compensation program. F2 · derivative.exercise_date: This option fully vests one year from the date of grant. Read SEC document
January 03, 2020 Filed Jan 7, 2020 17:00 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	SaleOrdinary Shares	1,536	$8.54	$13,117.44	Disclosure SEC source: 0000899243-20-000726 · doc4.xml · nonDerivative · entry 1 MACKEY CATHERINE J · CIK 0001645330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,748 F1 · shares: Represented by American Depositary Shares of the Issuer ("ADS"). Each ADS represents twelve ordinary shares of the Issuer. F2 · price: The price reported in Column 4 is a weighted average price per ordinary share ($102.46 per ADS). These share were sold in multiple transactions at prices ranging from $8.53 per ordinary share ($102.39 per ADS) to $8.54 per ordinary share ($102.47 per ADS), inclusive. The Reporting Person understands to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
July 25, 2019 Filed Jul 26, 2019 16:52 UTC	Avid Bioservices, Inc. CDMO · Entity 83494	GrantStock Option (right to buy) · Derivative	32,100	$0.00 Strike: $6.38	$0.00	Disclosure SEC source: 0001683168-19-002361 · ownership.xml · derivative · entry 1 MACKEY CATHERINE J · CIK 0001645330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,100 Underlying: Common Stock · 32,100 shares Expires 2026-07-25 F1 · derivative.exercise_date: This option vests in thirty-six (36) equal monthly installments over a three (3) year period beginning August 25, 2019 and each month thereafter until fully-vested. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.